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et al., 2000). In particular, IL-2 is pivotally involved inA Novel Means of Favorably Tipping
the AICD process whereas IL-15 inhibits IL-2-inducedthe Balance between Cytopathic AICD. Furthermore, IL-15 stimulates the maintenance of
memory phenotype T cells whereas IL-2 inhibits theirand Regulatory T Cells
persistence in vivo (Waldmann et al., 2001; Zhang et al.,
1998; Ku et al., 2000). Finally IL-2 is required for the
maintenance of the CD4CD25 negative regulatory
cells (Shevach, 2001). Thus IL-15 appears to be dedi-In this issue of Immunity, Zheng and coworkers pres-
cated toward the maintenance of a long-term memoryent a strategy to create transplantation tolerance with
and effector-immune response to antigens, an effectthree critical elements, the combined administration
that impairs allograft retention. IL-2 is involved in bothof rapamycin, an agonist IL-2/Fc, and an antagonist
the initial activation of cytotoxic T cells that interfere withmutant IL-15/Fc cytolytic-fusion protein to inhibit cyto-
allograft rejection and the generation of the peripheralpathic effects but retain negative regulatory T cells,
tolerance that is crucial for the retention of the allograftto permit allograft retention in animal models.
and for the prevention of autoimmune diseases. Thus,
in the immunotherapy directed toward the retention ofHarnessing the innate and adaptive immune systems to
allografts, one wishes to interrupt some IL-2-mediatedprovide long-lasting therapy for autoimmune diseases
actions while retaining others. Previously, the individualand to prevent allograft rejection are major goals of
or simultaneous administration of monoclonal antibod-immunotherapy. There have been significant advances
ies directed toward IL-2R and IL-2R has been usedin these efforts that involve the use of monoclonal anti-
to modulate the actions of IL-2 and IL-15 in the treatmentbodies, receptor-Fc fusion proteins, cytokines, and small
of autoimmune diseases and in the prevention of allograftmolecules that interrupt cytokine receptor signaling
rejection (Waldmann and O’Shea, 1998; Guex-Crosierpathways. These efforts have traditionally focused on
et al., 1997).abrogating the immune-effector responses mediated pre-
In this issue, Zheng and coworkers propose a strategydominantly by T lymphocytes including cytotoxic-
targeting the IL-2 and IL-15 systems to inhibit the cyto-effector cells. More recently, novel approaches have
pathic effects that are mediated by both cytokines butalso addressed a series of immunological checkpoints
also to retain the IL-2-dependent negative regulatorythat represent negative immunoregulatory safety mech-
T cells to create transplantation tolerance to yield long-anisms that are normally dedicated to preventing the
term allograft retention. These authors propose a strat-self-reactive, destructive immune responses that lead
egy with three critical elements, which include the com-to autoimmune diseases. Among the best studied of
bined administration of rapamycin, an agonist IL-2/Fc,these brakes on the immune system is the cytotoxic T
as well as an antagonist mutant IL-15/Fc cytolytic fusionlymphocyte antigen-4 (CTLA-4), a negative costimula-
protein to permit allograft retention in diverse animaltory molecule. Another negative regulatory control on
models. The rapamycin interrupts the cytokine receptorthe immune system is mediated by the phenomenon of
signals mediated by IL-2 and IL-15, thereby limiting the
activation-induced cell death (AICD) (Lenardo, 1996), a
early expansion of activated T cells, while permitting the
process that leads to the elimination of self-reactive
antigen-induced induction of IL-2 and its private IL-2R
T cells. A third checkpoint is mediated by CD4CD25
receptor that are involved in lymphocyte apoptotic
negative regulatory T cells (Tregs or suppressor cells) clearance, while preserving CD4CD25 negative im-
that impede effective immune responses to antigens munoregulatory networks. The mutant IL-15/Fc element
including transplantation antigens (Shevach, 2001). does not manifest IL-15 agonist functions, but rather
Targeting the IL-2 and IL-15 cytokine systems that interferes with the interaction of native IL-15 with its
regulate the life and death of lymphocytes represents receptor thereby preventing the unwanted effects of IL-
one of the emerging strategies to treat autoimmune dis- 15, including its actions in the maintenance of effector
eases and lymphoid malignancies and to facilitate allo- and memory CD8 cells as well as the role of IL-15 as
graft retention (Waldmann and O’Shea, 1998; Waldmann an inhibitor of AICD. Inclusion of the native IgG-Fc ele-
et al., 2001). The goal of this particular strategy is to ment in this cytolytic fusion protein facilitates the dele-
reduce the cytotoxic action mediated by activated im- tion by antibody-dependent cellular cytotoxicity (ADCC)
mune effector T cells involved in the rejection process of those activated T cells that express antigen-induced
while maintaining the negative immunoregulatory check- IL-15 receptors. The IL-2/Fc fusion protein is used to
points. IL-15 and IL-2 share two receptor subunits, IL- provide a survival factor for CD4CD25 regulatory
2R as well as the -c subunit that is also shared by T cells and to generate the IL-2-mediated agonist signals
IL-4, IL-7, IL-9, and IL-21 (Waldmann and Tagaya, 1999; involved in apoptotic clearance of self-reactive T cells.
Leonard, 2001). In addition, each cytokine receptor sys- This agent also acts to eliminate by ADCC the activated
tem includes a private cytokine specific  subunit, IL- T cells that express the private IL-2R receptor subunit,
15R and IL-2R. As might be anticipated from their a subunit that is present on the surface of antigen acti-
sharing of two subunits, IL-15 and IL-2 also share a vated T cells, but not on resting T cells. IL-2R is also
number of biological activities, especially those involved expressed by the CD4CD25 negative-regulatory T cells.
in the activation of T and- NK cells. However, especially Interestingly, neither the administration of rapamycin
in adaptive immune responses, they also provide dis- nor IL-2/Fc leads to the cytotoxic elimination of those
tinct and, at times, contrasting contributions to the sur- negative regulatory cells that are of importance in the
vival of lymphocytes that are involved in the immune maintenance of the transplant. This discordance in the
effects of IL-2/Fc on activated effector cells, as con-response (Waldmann et al., 2001; Zhang et al., 1998; Ku
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trasted with the negative regulatory cells both express- of IL-2 and IL-15 cytokines and their receptors in the
balance between cytopathic and regulatory cells to yielding CD25 (IL-2R), was not anticipated. The sparing of
the negative regulatory cells from the ADCC process a rational approach for the treatment of autoimmune
diseases and for the maintenance of allograft retentionmay reflect the lower levels of expression of IL-2R on
these cells when contrasted with that of fully activated (Zheng et al., 2003; Guex-Crosier et al., 1997).
effector T cells. The combined IL-2/Fc, mIL-15/Fc, and
rapamycin treatment had a number of desirable effects Thomas A. Waldmann
including the hastening of the expression of IL-2R National Cancer Institute
among activated T cells. Furthermore, as just noted, the National Institutes of Health
three element combination therapy exclusively acted Bethesda, Maryland 20892
upon activated T cells but spared the CD4CD25T cells
that were resistant to the lytic effects of IL-2/Fc. The Selected Reading
combination strategy involving IL-2/Fc, mutant IL-15/
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T.B. (2003). Immunity, this issue, 503–514.translated the emerging insights concerning the roles
Currently only two transcriptional regulators, X boxIt’s a Good Year for Blimp-1
protein-1 (XBP-1) and B lymphocyte induced maturation(and Plasma Cells) protein 1 (Blimp-1), have been shown to be involved in
plasma cell differentiation. Chimeric mice whose lymphoid
system lacks XBP-1 have a severe impairment in the
production of immunoglobulin of all isotypes despite
Immunoglobulin secreting plasma cells are critical the presence of normal numbers of T and B cells. Inspec-
mediators of an effective humoral immune response. tion of the peripheral lymphoid tissue revealed an ab-
In this issue of Immunity, an article by Shapiro-Shelef sence of plasma cells, demonstrating an absolute re-
et al. defines an essential role for the transcription quirement for XBP-1 in B cell terminal differentiation
factor Blimp-1 in plasma cell differentiation and pre- (Reimold et al., 2001). Now an article by Shapiro-Shelef
plasma memory B cell formation. et al. in this issue of Immunity provides definitive proof
that Blimp-1 is also essential for plasmacytic differenti-
During a primary humoral response, engagement of anti- ation.
gen-specific receptors on naive B cells initiates a series Blimp-1 (also called PRD1), isolated by Mark Davis’
of temporally and spatially regulated events that lead to laboratory almost a decade ago, was the first transcrip-
the differentiation of both memory B cells and antibody- tion factor described to drive B cell differentiation to the
secreting plasma cells. As terminally differentiated ef- plasma cell stage (Turner et al., 1994). This zinc finger
fector cells, plasma cells play an essential role in the protein is specifically expressed in a subset of germinal
humoral immune response by producing large amounts center B cells and plasma cells. Overexpression of
of immunoglobulin (Ig). These antibodies act as protec- Blimp-1 in the BCL1 cell line induces plasmacytic differ-
tive effector molecules in the elimination of invading entiation accompanied by J chain expression and Ig
pathogens. Conversely, production of autoreactive anti- secretion (Calame, 2001). Unequivocal proof that Blimp-1
bodies is pathogenic in autoimmune diseases such as was required for plasma cell differentiation was missing,
systemic lupus erythematosus. Therefore a better un- however, because of the early embryonic lethality of
derstanding of the molecular mechanisms involved in homozygous mutant embryos. Shapiro-Shelef et al.
plasma cell differentiation and Ig secretion are crucial have now solved this problem. They generated mice
for effective drug design targeting autoimmune diseases lacking Blimp-1 in B cells by crossing mice expressing
CD19-driven Cre recombinase with mice in which theand vaccine development.
